3) A randomized trial is conducted to evaluate the efficacy of a new cholesterol lowering

medication. The primary outcome is incident coronary artery disease. Participants are free of

coronary artery disease at the start of the study and randomized to receive either the new

medication or a placebo. Participants are followed for a maximum of 10 years for the

development of coronary artery disease.

The following data are:

Number participants number with coronary

artery disease

Cholesterol medication 400 28

Placebo 400 42

A)

Compute the Relative Risk of coronary artery disease in patients receiving the new

medication as compared to placebo.

Relative Risk =

B)

Compute the Odd ratio of coronary artery disease in patients receiving the new medications

as compared to placebo

Odds Ratio =